Industry News Novo Nordisk BioPharma Dive
Novo files etavopivat for sickle cell disease in the US and Europe
- Novo Nordisk has submitted US and European marketing applications for etavopivat, a once-daily oral treatment for sickle cell disease.
- The drug came from the roughly $1 billion Forma Therapeutics acquisition; Novo describes it as a potential new standard of care and a future blockbuster.
- Etavopivat is also in mid-stage testing for thalassemia.
For a company defined by obesity, a rare-disease filing is a quiet portfolio hedge, and an oral once-daily option fits a market still dominated by infusions and gene therapies. The comparison that matters is with Agios's mitapivat, another PK activator moving toward sickle cell: no head-to-head exists, so label wording on crisis reduction versus haemoglobin response will decide positioning.
Source: BioPharma Dive ↗ Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties